Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Ximin Chen(Chengdu Women's and Children's Central Hospital), Yvonne Y. Chen(University of California, Los Angeles)
Cited by 18
Related Papers
Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
|Annual Review of Chemical and Biomolecular Engineering|2022|35
SENP5 acts as a downstream target of androgen receptor and contributes to prostate cancer growth
|Oncology Letters|2025|0